Evidence map›Paper›PMID 40277885›Full record

ArticleCells2025

A Personalized 14-3-3 Disease-Targeting Workflow Yields Repositioning Drug Candidates.

Yonika A Larasati, Gonzalo P Solis, Alexey Koval, Christian Korff, Vladimir L Katanaev

Abstract read
In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yonika A LarasatiTranslational Research Center in Oncohaematology, Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, CH-1211 Geneva, Switzerland.ORCID 0000-0002-9423-0768
Gonzalo P SolisTranslational Research Center in Oncohaematology, Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, CH-1211 Geneva, Switzerland.ORCID 0000-0002-2359-3780
Alexey KovalTranslational Research Center in Oncohaematology, Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, CH-1211 Geneva, Switzerland.
Christian KorffPediatric Neurology Unit, University Hospitals of Geneva, CH-1211 Geneva, Switzerland.ORCID 0000-0002-3328-7680
Vladimir L KatanaevTranslational Research Center in Oncohaematology, Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, CH-1211 Geneva, Switzerland.ORCID 0000-0002-7909-5617

Funding

Aga Khan Foundation N/AFondation de l'Hôpital de La Tour N/AFondation Privée des HUG N/A
6 · The paper itself

Abstract

Rare diseases typically evade the application of the standard drug discovery and development pipelines due to their understudied molecular etiology and the small market size. Herein, we report a rare disease-directed workflow that rapidly studies the molecular features of the disorder, establishes a high-throughput screening (HTS) platform, and conducts an HTS of thousands of approved drugs to identify and validate repositioning drug candidates. This study examines the pediatric neurological disorder caused by de novo mutations in

Indexed as

14-3-3 ProteinsDrug RepositioningPrecision MedicineHigh-Throughput Screening AssaysHumansMutationProtein BindingWorkflow14-3-3 Proteins14-3-3γassay developmentdrug discoverydrug repositioningpediatric encephalopathyphosphoproteinsrare diseasesYWHAG

Identifiers

PMID40277885
PMCPMC12025923

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.